- OT
- View all news
- Patient perspective in the spotlight during 2026 Spectacle Makers’ Lecture
Patient perspective in the spotlight during 2026 Spectacle Makers’ Lecture
Professor David Crabb delivered a presentation exploring new ways of understanding the effect of age-related eye disease on patients
17 November 2026
City St George’s University of London ,Professor David Crabb outlined research exploring the patient perspective of age-related eye disease during the 2026 Spectacle Makers’ Lecture (2 November, London).
Crabb highlighted that many of the projects undertaken through the Crabb Lab examine the burden of eye disease.
He added that the number of people with age-related eye disease, such as glaucoma, is increasing in line with the ageing population.
“When I was at school, I was taught about population pyramids – a pyramid of people with younger people at bottom, and elderly people at the top. And as we all know, this is changing. Demographics are changing,” he said.
Crabb explained that traditionally there has been a focus on measuring intraocular pressure (IOP) in glaucoma – as a modifiable risk factor for disease progression.
The professor of statistics and vision research noted that the Crabb Lab has previously undertaken research across multiple UK hospitals that found clinical management decisions in glaucoma were made on the basis of IOP control.
“Even though we’re getting much better at using imaging to look at the site of disease, which in glaucoma is the optic nerve, imaging isn’t really used to manage patients,” Crabb observed.
He highlighted the important role that visual field tests play in monitoring people with glaucoma.
“I believe that perimetry, which is a measure of visual function – what a patient can actually see with this condition – is the most important measurement,” Crabb said.
Crabb outlined how a series of Crabb Lab projects over the past 15 years have looked beyond the numbers on a patient’s clinical chart to interrogate what eye disease means for their daily life.
“We might see by looking at the clinical chart that the patient’s vision is deteriorating. For example, we can look at the size of a lesion in geographic atrophy and show that the disease is worsening over time, but what does this really mean for the patient?” he said.
Crabb shared that patients often want to know how an eye condition will affect their ability to perform everyday tasks – such as reading or identifying a label on a supermarket shelf.
“When are they going to begin to find it difficult to do tasks around the home, like making a cup of coffee? When will their vision affect their mobility and their risk of having a fall?” he asked.
The academic detailed a Crabb lab study where researchers examined study participants’ prehension – their ability to reach out and grasp an object.
The research illustrated how patients with visual field loss struggled with this skill.
“It highlighted the importance of the location of the visual field loss,” Crabb said.
He noted that qualitative research performed by the lab has explored what people with eye conditions are anxious about.
“One of their main fears when they were diagnosed with an eye condition was that they would lose their driving licence. That is clearly a real priority for patients,” Crabb said.
He outlined research that explored the effect of visual field loss on hazard perception when driving, using eye tracking data to compare where those with eye conditions looked compared to healthy controls.
Crabb also described a study that examined the ability of patients with eye conditions to search for objects – for example, to find an item on a supermarket shelf or to find a sign in a railway station.
“What I found interesting is that you could take two people with almost identical visual field records, almost identical clinical measurements, but one performs very well on the task, and one performs very badly,” he said.
“Often the measurements that we take in the clinic may not capture some of these real-world visual activities,” Crabb highlighted.
Comments (0)
You must be logged in to join the discussion. Log in